Search
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigational[L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC). … Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersIpecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawnIpecac is obtained from the plant _Cephaelis ipecacuanha_ and contains a number of emetic alkaloids including emetine and cephaeline. … [L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCinaciguat
go.drugbank.com/drugs/DB16126InvestigationalCinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients
Cilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigational[L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894]
Mixtures: Imipenem and Cilastatin Powder for Injection USP 250 mg/250 mg, Imipenem/Cilastatin Stravencon 250 mg/250 mg Pulver zur Herstellung einer InfusionslösungSynonyms: (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine, (L)-7-(2-Amino-2-carboxy-ethylsulfanyl)-2-[(2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acidLevomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigationalLevomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. … [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawnand 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary) [L4019, L4021, L4022]. … This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1, TrcB/B1, TrcC/C1, and other more minor contributors)
Mixtures: Dorithricin Halstabletten Classic 0,5 mg / 1,0 mg / 1,5 mg Lutschtabletten, Dorithricin Halstabletten Waldbeergeschmack 0,5 mg / 1,0 mg / 1,5 mg LutschtablettenBG-777
go.drugbank.com/drugs/DB05839ExperimentalBG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
Aluminum chlorohydrex propylene glycol
go.drugbank.com/drugs/DB11208ApprovedAluminum chlorohydrex propylene glycol is a complex consisting of Aluminum Chorohydrate and propylene glycol (PG).
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[A260122,A260127] Ritlecitinib binds covalently to Cys-909 of JAK3, a site where other JAK isoforms have a serine residue. … [A260122,A260127] Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsPG-530742
go.drugbank.com/drugs/DB05495InvestigationalStudies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis. … PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis.